Is carprofen or Rimadyl safe for cats? What NSAIDs can ca...

Regarding NSAID use in cats, this is a critical area where species-specific pharmacokinetic differences profoundly impact safety and efficacy. Let's break down the options for your 12-year-old DSH with osteoarthritis.

Is Carprofen (Rimadyl) Safe for Cats?

No, carprofen (Rimadyl) is not FDA-approved for use in cats, and its off-label use carries significant risk. The primary reason lies in the fundamental feline deficiency in glucuronidation, a Phase II metabolic pathway. Carprofen relies heavily on glucuronidation for its elimination. In cats, this leads to a dramatically prolonged half-life (up to 30 hours or more compared to ~8 hours in dogs), increasing the risk of drug accumulation and toxicity, particularly hepatotoxicity and nephrotoxicity. While some veterinarians have historically used it off-label for very short durations at reduced doses, it is generally discouraged due to the availability of safer, FDA-approved alternatives.

General NSAID Principles in Cats

Cats are uniquely sensitive to NSAIDs due to their limited glucuronidation capacity and distinct renal physiology. Any NSAID use in cats, especially long-term, requires careful patient selection, appropriate dosing, and rigorous monitoring. Hydration status is paramount.

NSAIDs for Long-Term Feline OA Management

For a 12-year-old DSH, the focus should be on minimizing renal and hepatic burden, as these patients often have subclinical or overt organ dysfunction. We have three main categories to consider: meloxicam, robenacoxib, and the newer non-NSAID monoclonal antibody therapy.

#

1. Meloxicam (Metacam®)

* Pharmacology: Meloxicam is a preferential COX-2 inhibitor. While it does have some glucuronidation, its primary metabolism is through oxidative pathways. Its half-life in cats is approximately 15-20 hours.
Regulatory Status: In the US, the injectable formulation is FDA-approved for a single subcutaneous dose in cats for perioperative pain. The oral suspension is not* FDA-approved for chronic use in cats in the US, although it is approved for long-term use in the EU.
* Concerns: Historically, there have been reports of renal failure associated with long-term oral meloxicam use in cats, leading to a "black box warning" on the injectable product in the US. This is particularly relevant for older cats with potential pre-existing renal compromise.
* Dr. Voss's Stance: If meloxicam is considered for long-term OA management (usually when other options are unavailable or ineffective), it must be used with extreme caution, at the lowest effective dose (e.g., 0.02-0.03 mg/kg PO q24h, or even q48h on some protocols) and with strict monitoring of renal parameters (BUN, creatinine, SDMA, urine specific gravity) every 3-6 months. Pre-treatment hydration and avoiding concurrent nephrotoxic drugs are essential. This is an off-label use in the US and requires a thorough owner discussion of risks vs. benefits.

#

2. Robenacoxib (Onsior®)

* Pharmacology: Robenacoxib is a highly COX-2 selective NSAID with a unique pharmacokinetic profile in cats. It has a very short half-life in the bloodstream (around 1-2 hours) but rapidly and preferentially accumulates at sites of inflammation, where it remains for an extended period. It is primarily metabolized by the liver, with minimal renal excretion.
* Regulatory Status: FDA-approved for up to 6 days for acute pain in cats. However, it is approved for long-term daily use in cats with OA in Europe and Canada.
* Safety Profile: Due to its rapid systemic clearance, tissue selectivity, and minimal renal excretion, robenacoxib is generally considered to have a more favorable safety profile for long-term use in cats compared to meloxicam, particularly concerning renal impact.
* Dr. Voss's Stance: Given its specific approval for long-term use in other regions and its feline-friendly PK, robenacoxib (1 mg/kg PO q24h) is a preferred NSAID option for chronic OA pain in cats when an NSAID is indicated. Regular monitoring of renal and hepatic parameters (q6-12 months) is still prudent, especially in a 12-year-old cat.

#

3. Frunevetmab (Solensia®) - The New FDA-Approved Option

* Pharmacology: Frunevetmab is a truly novel approach. It is a monoclonal antibody (mAb) that targets Nerve Growth Factor (NGF), a key mediator in pain pathways, especially chronic pain like OA. By binding to NGF, it prevents the activation of pain receptors. As a large protein, it is metabolized via protein catabolism, not through hepatic (CYP450, glucuronidation) or renal pathways.
* Regulatory Status: FDA-approved for the control of pain associated with osteoarthritis in cats.
* Safety Profile: This is its major advantage. Because it is a mAb, it has no direct hepatic or renal metabolism or excretion, making it an extremely attractive option for older cats, especially those with pre-existing or subclinical kidney disease. It has a very low risk of drug-drug interactions. The most common side effects observed in clinical trials were mild injection site reactions.
* Dosing: Administered subcutaneously once a month. The dose is weight-banded (1-2.8 mg/kg SC once monthly).
* Dr. Voss's Stance: For a 12-year-old DSH with OA, frunevetmab (Solensia®) is the first-line recommendation for long-term OA pain management. Its novel mechanism, excellent safety profile (especially for organ function), and convenient monthly dosing make it superior to NSAIDs in many senior feline patients. It removes the NSAID-associated renal and GI risks entirely.

Comparison for Your 12-Year-Old DSH

Considering your cat's age, the potential for subclinical organ dysfunction (especially CKD, which is highly prevalent in senior cats), and the goal of long-term management:

Frunevetmab (Solensia®) is the top choice. It offers effective pain control without the renal or hepatic risks associated with traditional NSAIDs. This is a game-changer for feline OA.

Robenacoxib (Onsior®) would be the preferred NSAID option if an NSAID is deemed necessary (e.g., if Solensia is not effective enough on its own, or due to cost considerations). Its favorable feline PK profile makes it safer for chronic use than meloxicam.

Meloxicam (Metacam®) should be considered a last resort for long-term NSAID use in cats, and only with extreme caution, at the lowest effective dose, and with frequent, diligent monitoring of renal parameters.

Before initiating any long-term pain medication, a thorough diagnostic workup, including a complete blood count, serum biochemistry profile (including SDMA), and urinalysis, is essential to establish baseline organ function. This is especially true for NSAIDs.

Remember, NSAIDs primarily address inflammation. Other adjunctive therapies, such as environmental modifications, weight management, and nutraceuticals (e.g., glucosamine/chondroitin, omega-3 fatty acids), should also be considered as part of a multimodal pain management plan.